Tuesday, 18 Feb 2020

You are here

Selective Use of HLA-B*5801 Testing in Gout

The current edition of JAMA Internal Medicine describes an Asian gout patient who presents with an allopurinol hypersensitivity reaction that could have been diagnosed by testing for HLA-B*5801.

The patient was an elderly Asian male with chronic stage 3 kidney disease, gout, and hypertension. He was prescibed allopurinol (300 mg daily) and colchicine, 0.6 mg daily for acute gout attacks and then a month later presented with acute fever of  102.3°F, myalgia, maculopapular rash over the trunk and arms and laboratory evidence of leukopenia, mild eosinophilia and elevated hepatic enzymes (ALT 308 U/L and AST 248 U/L). 

Drug rash with eosinophilia and systemic symptoms (DRESS) was suspected and allopurinol was discontinued; testing was positive for HLA-B*5801.  He had a complicated course requiring more than 2 months in the hospital.

The allopurinol hypersensitivity syndrome is rare (1 in 1000) and manifests with severe cutaneous reactions that may present as DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis, etc. 

While HLA-B*5801 is found in 6-12% of certain Asian populations, it is very uncommon in whites (<1.0%) and less common in African Americans (3.8). Thus it is not commonly recommended in these patient groups.

HLA-B*5801 is very prevalent in the Han Chinese, Thai, and Korean people.  In this instance, predictive association between this allele and allopurinol hypersensitivity is very high (Hazard Ration ~ 100) suggesting its testing would be appropriate prior to prescribing allopurinol in certain asian populations. Finding HLA-B*5801 positivity is an indication for urate lowering therapy other than allopurinol.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.